The US FDA has approved Regeneron Pharmaceuticals' drug Pasatru (garetosmab) to treat fibrodysplasia ossificans progressiva (FOP), a rare genetic bone disorder. The drug demonstrated a 94% reduction in new bone abnormalities during clinical trials. While this approval expands the company's rare disease portfolio, investors should note the drug addresses an ultra-rare patient population and faces established competition.
Regeneron Pharmaceuticals secured US FDA approval on August 19, 2026, for its monoclonal antibody, Pasatru (garetosmab), aimed at treating adults with fibrodysplasia ossificans progressiva (FOP). This rare genetic disorder causes the body's soft tissue to progressively turn into bone, creating a second skeleton that restricts movement and shortens life expectancy. Following the announcement, Regeneron's stock price rose by approximately 4% in trading.
Clinical Results and Market Entry
The FDA approval follows data from the Phase 3 OPTIMA trial, which demonstrated that Pasatru significantly inhibits Activin A, a protein linked to the abnormal bone growth seen in FOP patients. According to trial results, patients receiving a 3 mg/kg dose experienced a 94% reduction in new heterotopic ossification—or abnormal bone—lesions over 56 weeks, while those on a 10 mg/kg dose saw a 90% reduction compared to a placebo group. Pasatru now enters a niche market, becoming the second treatment option available for FOP patients following Ipsen’s Sohonos.
Business Context and Risks
While the drug offers a new therapy for an ultra-rare condition, the addressable patient population is very small, with approximately 900 diagnosed cases globally. This limits the potential for large-scale revenue generation compared to more common conditions. Investors should also be aware of the company's past challenges with this program; Regeneron had previously paused clinical trials in 2020 following the deaths of five patients. The company subsequently worked with global regulators to address these safety concerns, leading to the current successful trial design.
Beyond trial history, the drug carries potential side effects, including the risk of infection, acne, hair growth changes, and nosebleeds. As with any specialty medicine, safety monitoring remains a critical factor for long-term clinical success.
Next Steps for the Company
Looking ahead, Regeneron has indicated plans to initiate trials for pediatric patients with FOP later this year. The company's ability to capture market share from existing treatments and manage the regulatory and safety requirements for such a specialized therapy will be the key monitorable for the business moving forward.